Related Experiment Video
Updated: Dec 13, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.2K
Perioperative glucose management: Current status and future directions
1Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Best Practice & Research. Clinical Anaesthesiology
|July 27, 2020
Summary
Managing hyperglycemia in surgical patients is crucial for reducing complications. Novel diabetes technologies and multidisciplinary collaboration are key to improving perioperative glucose control and patient outcomes.
Area of Science:
- Endocrinology
- Surgical Care
- Diabetes Management
Background:
- Hyperglycemia is prevalent in surgical patients, increasing morbidity and mortality.
- Current perioperative care involves glucose monitoring and insulin therapy, with a target below 10.0 mM.
- Challenges include staffing shortages and increasing case complexity.
Purpose of the Study:
- To review current practices in perioperative glucose management.
- To explore the potential of novel diabetes technologies in surgical settings.
- To emphasize the need for evidence-based, standardized perioperative diabetes care.
Main Methods:
- Literature review of perioperative glucose management strategies.
- Discussion of consensus on intraoperative glucose control.
- Exploration of emerging diabetes technologies (CGM, insulin pumps, closed-loop systems).
Main Results:
- Established consensus on maintaining intraoperative glucose levels below 10.0 mM.
- Identified potential of new diabetes technologies to address unmet needs.
- Highlighted the necessity for well-designed clinical trials.
Conclusions:
- Novel diabetes technologies offer promise for improving perioperative diabetes care.
- Evidence-based, standardized practices are needed, requiring further clinical trials.
- Multidisciplinary collaboration among anesthesiologists, surgeons, and endocrinologists is essential.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
767
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
767
01:15Hypoglycemia and Glucagon
676
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
676
01:02Glucose Homeostasis: Regulation of Blood Glucose
3.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.5K
01:22Diabetes Mellitus: Type 2 and Gestational
4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
01:06Oral Hypoglycemic Agents: Glinides
478
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
478
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.9K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.9K